Drug-nutrient interaction refers to an alteration of kinetics or dynamics of a drug or a nutritional element, or a compromise in nutritional status as a result of the addition of a drug. The potentials for drug—nutrient interaction increase with the number of drugs taken by the patient. Organ transplant recipients are therefore at high risk for drug-nutrient interactions because multiple medications are used to manage graft rejection, opportunistic infections, and other associated complications. Unrecognized or unmanaged drug-nutrient interactions in this patient population can have an adverse impact on their outcomes. This paper reviews the importance of recognizing drug-nutrient interaction when using cyclosporine-based regimens. (Journal of Parenteral and Enteral Nutrition25:132-141, 2001)
Get full access to this article
View all access options for this article.
References
1.
Melander A. : Influence of food on the bioavailability of drugs. Clin Pharmacokinet3:337-351, 1978
2.
Ohtani Y., Endo F., Matsuda I.: Carnitine deficiency with hyperammonemia associated with valproic acid therapy . J Pediatr101:782-785, 1982
3.
Zaccara G., Paganini M., Campostrini R., et al: Hyperammonemia and valproate-induced alterations of the state of consciousness. A report of 8 cases. Eur Neurol23:104-112, 1984
4.
Thurston JH, Hauhart RE: Amelioration of adverse effects of valproic acid on ketogenesis and liver coenzyme. A metabolism by cotreatment with pantothenate and carnitine in developing mice: Possible clinical significance. Pediatr Res31:419-423, 1992
5.
Sugimoto T., Nishida N., Murakami K., et al: Valproate-induced hepatoxicity: Protective effect of L-carnitine supplementation. Jpn J Psychiatry Neurol44:387-388, 1990
6.
Bohles H., Sewell AC, Wenzel D.: The effect of carnitine supplementation in valproate-induced hyperammonaemia . Acta Paediatr85:446-449, 1996
7.
Beversdorf D. , Allen C., Nordgren R.: Valproate-induced encephalopathy treated with carnitine in an adult [letter]. J Neurol Neurosurg Psychiatry61:211, 1996
8.
Triggs WJ, Gilmore RL, Millington DS, et al: Vlaproate-associated carnitine deficiency and malignant cerebral edema in the absence of hepatic failure. Int J Clin Pharmcol Thera35:353-356, 1997
9.
Chan L.: Redefining drug nutrient interactions. Nutr Clin Pract15:249-252, 2000
10.
Diasio RB, LoBuglio AF Immunomodulators: Immunosuppressive agents and immunostimulants. IN Goodman & Gilman's The Pharmacological Basis of Therapeutics , 9th ed, Hardman JG, Limbird LE, Molinoff PB, Ruddon RW , Gilman AG, (eds). McGraw-Hill Co., Inc., New York, 1996, pp 1296-1304
11.
Bantle JP, Nath KA, Sutherland DE, et al: Effects of cyclosporine on the renin-angiotensin-aldosterone system and potassium excretion in renal transplant recipients. Arch Intern Med145(3): 505-508, 1985
12.
Preston RA, Hirsh MJ, Oster JR, et al: University of Miami Division of Clinical Pharmacology therapeutic rounds: Drug-induced hyperkalemia. Am J Ther5:125-132, 1998
13.
Wong NLM , Dirks JH: Cyclosporin-induced hypomagnesemia and renal magnesium wasting in rats. Clin Sci75:509-514, 1988
14.
Bennett WM, Burdmann E., Andoh T., et al: Nephrotoxicity of immunosuppressive drugs. Miner Electrolyte Metab20:214-220, 1994
15.
Boncimino K. , McMahon DJ, Addesso V., et al: Magnesium deficiency and bone loss after cardiac transplantation. J Bone Miner Res14:295-303, 1999
16.
Thompson CB , June CH, Sullivan KM, et al: Association between cyclosporine neurotoxicity and hypomagnesemia. Lancet2:1116-1120, 1984
17.
Mori S., Harada S., Okazaki R., et al: Hypomagnesemia with increased metabolism of parathyroid hormone and reduced responsiveness to calcitropic hormones. Intern Med31:820-824, 1992
18.
Navarro JF, Mora C., Jimenez A., et al: Relationship between serum magnesium and parathyroid hormone levels in hemodialysis patients. Am J Kidney Dis34:43-48, 1999
19.
Ichihara A. , Suzuki H., Saruta T.: Effects of magnesium on the renin-angiotensin-aldosterone system in human subjects. J Lab Clin Med122:432-440, 1993
20.
Thiebaud D. , Krieg MA, Gillard-Berguer D., et al: Cyclosporine induces high bone turnover and may contribute to bone loss after heart transplantationEur J Clin Invest 26:549-555, 1996
21.
Grenet O. , Bobadilla M., Chibout S.: Evidence for the impairment of the vitamin D activation pathway by cyclosporine A. Biochem Pharmacol59:267-272, 2000
22.
Welch GN , Loscalzo J.: Homocysteine and atherothrombosis. N Engl J Med338:1042-1050, 1998
23.
Langman LJ , Ray JG, Evrovski J., et al: Hyperhomocyst(e)inemia and the increased risk of venous thromboembolism: More evidence from a case-control study. Arch Intern Med160:961-964, 2000
24.
Eikelboom JW , Lonn E., Genest J. Jr, et al: Homocyst(e)ine and cardiovascular disease: A critical review of the epidemiologic evidence . Ann Intern Med131:363-375, 1999
25.
Moustapha A. , Naso A., Nahlawi M., et al: Prospective study of hyperhomocys-teinemia as an adverse cardiovascular risk factor in end-stage renal disease [published erratum appears in Circulation1998;97:711] . Circulation97:138-141, 1998
26.
Nygard O. , Nordrehaug JE, Refsum H., et al: Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med337:230-236, 1997
27.
Arnadottir M. , Hultberg B., Nilsson-Ehle P., et al: The effect of reduced glomerular filtration rate on plasma total homocysteine concentration . Scand J Clin Lab Invest56:41-46, 1996
28.
Robinson K. , Gupta A., Dennis V., et al: Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations . Circulation94:2743-2748, 1996
29.
Dennis VW , Robinson K.: Homocysteinemia and vascular disease in end stage renal disease. Kidney Int50(Suppl 57):S11-S17, 1996
30.
Wilcken DEL , Gupta VJ, Betts AK: Homocysteine in the plasma of renal transplant recipients: Effects of cofactors for methionine metabolism. Clin Sci61:743-749, 1981
31.
Massy ZA , Chadefaux-Vekemans B., Chevalier A., et al: Hyperhomocysteinaemia : A significant risk factor for cardiovascular disease in renal transplant recipients . Nephrol Dial Transplant9:1103-1108, 1994
32.
Arnadottir M. , Hultberg B., Vladov V., et al: Hyperhomocysteinemia in cyclosporine-treated renal transplant recipients. Transplantation61:509-512, 1996
33.
Ducloux D. , Fournier V., Rebibou J-M., et al: Hyperhomocyst(e)inemia in renal transplant recipients with and without cyclosporine. Clin Nephol49:232-235, 1998
34.
Arnadottir M. , Hultberg B., Wahlberg J., et al: Serum total homocysteine concentration before and after renal transplantation. Kidney Int54:1380-1384, 1998
35.
Cole DEC , Ross HJ, Evrovski J., et al: Correlation between total homocysteine and cyclosporine concentrations in cardiac transplant recipients . Clin Chem44:2307-2312, 1998
36.
Lindholm A. , Welsh M., Alton C., et al: Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: Racial differences in bioavailability . Clin Pharmacol Ther52:359-371, 1992
37.
Neylan JF: Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group. Transplantation65:515-523, 1998
38.
Arnadottir M., Hultberg B.: Treatment with high-dose folic acid effectively lowers plasma homocysteine concentration in cyclosporine-treated renal transplant recipients [letter]. Transplantation64:1087, 1997
39.
Beaulieu AJ , Gohh RY, Han H., et al: Enhanced reduction of fasting total homocysteine levels with supraphysiological versus standard multivitamin dose folic acid supplementation in renal transplant recipients . Arterioscler Thromb Vasc Biol19:2918-2921, 1999
40.
Sokol RJ, Johnson KE, Karrer FM, et al: Improvement of cyclosporine absorption in children after liver transplantation by means of water-soluble vitamin E. Lancet338:212-215, 1991
41.
Boudreaux JP , Hayes DH, Mizrahi S., et al: Use of water-soluble liquid vitamin E to enhance cyclosporine absorption in children after liver transplant . Transplant Proc25:1875, 1993
42.
Pan S. , Lopez RR, Sher LS, et al: Enhanced oral cyclosporine absorption with water-soluble vitamin E early after liver transplantation. Pharmacotherapy16:59-65, 1996
43.
Chang T., Benet LZ, Hebert MF: The effect of water-soluble vitamin E on cyclosporine pharmacokinetics in healthy volunteers. Clin Pharmacol Ther59:297-303, 1996
44.
Gatmaitan ZC , Arias IM: Structure and function of P-glycoprotein in normal liver and small intestine . Adv Pharmacol24:77-97, 1993
45.
Van Asperen J. , Van Tellingen O., Beijnen JH: The pharmacological role of P-glycoprotein in the intestinal epithelium. Pharmacol Res37:429-435, 1998
46.
Dintaman JM , Silverman JA: Inhibition of P-glycoprotein by D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm Res16:1550-1556, 1999
47.
Bailey DG, Malcolm J., Arnold MO, et al: Grapefruit juice-drug interactions. Br J Clin Pharmacol46:101-110, 1998
48.
Bailey DG, Spence JD, Edgar B., et al: Ethanol enhances the hemodynamic effects of felodipine. Clin Invest Med12:357-362, 1989
49.
Rendic S., Di Carlo FJ: Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev29:413-580, 1997
50.
Fuhr U.: Drug interactions with grapefruit juice. Extent, probable mechanism and clinical relevance. Drug Safety18:251-272, 1999
51.
Herlitz H., Edgar B., Hedner T., et al: Grapefruit juice: A possible source of variability in blood concentration of cyclosporin A [letter]. Nephrol Dial Transplant8:375, 1993
52.
Hollander Aamj , Van Rooij J., Lentjes Egwm, et al: The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients. Clin Pharmacol Ther57:318-324, 1995
53.
Yee GC, Stanley DL, Pessa LJ, et al: Effect of grapefruit juice on blood cyclosporin concentration . Lancet345:955-956, 1995
54.
Ducharme MP , Warbasse LH, Edwards DJ: Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther57:485-491, 1995
55.
Proppe DG, Hoch OD, McLean AJ, et al: Influence of chronic ingestion of grapefruit juice on steady-state blood concentrations of cyclosporine A in renal transplant patients with stable graft function [letter]. Br J Clin Pharmacol39:337-338, 1995
56.
Ioannides-Demos LL, Christophidis N., Ryan P., et al: Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases. J Rheumatol24:49-54, 1997
57.
Fuhr U., Klittich K., Staib AH: Inhibitory effect of grapefruit juice and the active component, naringenin, on CYP1A2 dependent metabolism of caffeine. Br J Clin Pharmacol35:431-436, 1993
58.
Fuhr U., Kummert AL: The fate of naringin in humans: A key to grapefruit juice-drug interactions?Clin Pharmacol Ther58:365- 373, 1995
59.
Ubeaud G., Hagenbach J., Vandenschrieck S., et al: In vitro inhibition of simvastatin metabolism in rat and human liver by naringenin. Life Sci65:1403-1412, 1999
60.
Rashid J.McKinstry C.Renwick AG, et al: Quercetin, an in vitro inhibitor of CYP3A4. does not contribute to the interaction between nifedipine and grapefruit juice. Br J Clin Pharmacol36:460-463, 1993
61.
Bailey DGArnold MOMunoz C., et al: Grapefruit juice-felodipine interaction: Mechanism, predictability, and effect of naringin. Clin Pharmacol Ther53:637-642, 1993
62.
Edwards DJ, Bernier SM: Naringin and naringenin are not the primary CYP3A inhibitors in grapefruit juice. Life Sci59:1025-1030, 1996
63.
Fukuda K., Ohta T., Yamazoe Y.: Grapefruit component interacting with rat and human CYP3A: Possible involvement of nonflavonoid components in drug interactions. Biol Pharm Bull20:560-564, 1997
64.
Edwards DJ, Bellevue FH III, Woster PM: Identification of 6'7'dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice. Drug Metab Dispos24:1287-1290, 1996
65.
Edwards DJ, Fitzsimmons ME, Schuetz EG, et al: 6',7'-Dihydroxybergamottin in grapefruit juice and Seville orange juice: Effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein . Clin Pharmacol Ther65:237-244, 1999
66.
Soldner A., Christians U., Susanto M., et al: Grapefruit juice activates P-glycoprotein-mediated drug transport . Pharm Res16:478-485, 1999
67.
Eagling VA, Profit L., Back DJ: Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components . Br J Clin Pharmacol48:543-552, 1999
68.
Lown KS, Mayo RR, Leichtman AB, et al: Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther62:248-260, 1997
69.
Hall SD, Thummel KE, Watkins PB: Molecular and physical mechanisms of first-pass extraction. Drug Metab Dispos27:161-166, 1999
70.
Ito K., Kusuhara H., Sugiyama Y.: Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption-theoretical approach. Pharm Res16:225-231, 1999
71.
Lown KS, Bailey DG, Fontana RJ, et al: Grapefruit juice increases felodipine oral bioavailability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest99:2545- 2553, 1997
72.
Schmiedlin-Ren P., Edwards DJ, Fitzsimmons ME, et al: Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents: Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab Dispos25:1228-1233, 1997
73.
Fellers PJ, Nikdel S., Lee HS: Nutrient content and nutrition labeling of several processed Florida citrus juice products. J Am Diet Assoc90:1079-1084, 1990
74.
Hansten PD: Understanding drug-drug interaction. Sci Med Jan/Feb:16-25, 1998
